AbbVieの空売り状況は、投資家がAbbVieの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

AbbVie (NYSE:ABBV) 株価情報, 空売り情報

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie Inc

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Biotech

Government

Large Cap

Regulations

Health Care

General

AMGN

TEVA

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

AbbVie Exec Says Co Can Commit Less Capital Particularly In Drugs For Psychiatric Disorders

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$25.00</td>
<td>$380.0K</td>
<td>2.3K</td>
<td>3.5K</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$115.00</td>
<td>$64.3K</td>
<td>26</td>
<td>3.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$26.00</td>
<td>$48.1K</td>
<td>12.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ONC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$40.5K</td>
<td>0</td>
<td>406</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$75.0K</td>
<td>39</td>
<td>302</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$175.00</td>
<td>$90.1K</td>
<td>7.2K</td>
<td>170</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$40.7K</td>
<td>203</td>
<td>167</td>
</tr>
<tr>
<td>OPCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$37.6K</td>
<td>208</td>
<td>157</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$55.00</td>
<td>$55.3K</td>
<td>421</td>
<td>154</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$30.6K</td>
<td>556</td>
<td>139</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option trade with neutral sentiment. It expires in 66 day(s) on March 21, 2025. Parties traded 1000 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $380.0K, with a price of $380.0 per contract. There were 2393 open contracts at this strike prior to today, and today 3522 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bullish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 99 contract(s) at a $115.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $64.3K, with a price of $645.0 per contract. There were 26 open contracts at this strike prior to today, and today 3057 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 501 contract(s) at a $26.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $96.0 per contract. There were 12780 open contracts at this strike prior to today, and today 1248 contract(s) were bought and sold. 
• Regarding ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 33 contract(s) at a $180.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $40.5K, with a price of $1230.0 per contract. There were 0 open contracts at this strike prior to today, and today 406 contract(s) were bought and sold. 
• For BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $145.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $75.0K, with a price of $750.0 per contract. There were 39 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 142 contract(s) at a $175.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $90.1K, with a price of $635.0 per contract. There were 7210 open contracts at this strike prior to today, and today 170 contract(s) were bought and sold. 
• Regarding HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 167 contract(s) at a $35.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $40.7K, with a price of $245.0 per contract. There were 203 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
• Regarding OPCH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on January 17, 2025. Parties traded 47 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $801.0 per contract. There were 208 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a put option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 82 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $55.3K, with a price of $679.0 per contract. There were 421 open contracts at this strike prior to today, and today 154 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bearish, expiring in 3 day(s) on January 17, 2025. This event was a transfer of 42 contract(s) at a $580.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $730.0 per contract. There were 556 open contracts at this strike prior to today, and today 139 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

OPCH

PRAX

10 Health Care Stocks With Whale Alerts In Today's Session

On Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) agreed to acquire Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) for $132.00 per share in cash for a total equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940221/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-i" rel="noreferrer noopener">approximately $14.6 billion</a>.
Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41752158/intra-cellular-therapies-treatment-reduces-schizophrenia-relapse-risk-63" rel="noreferrer noopener">Intra-Cellular Therapies&#8217; Treatment Reduces Schizophrenia Relapse Risk 63%</a>
With this agreement, Johnson &amp; Johnson adds Intra-Cellular Therapies&#8217; Caplyta&nbsp;(lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer&#8217;s disease-related psychosis and agitation, as well as a clinical-stage pipeline that further complements and strengthens Johnson &amp; Johnson&#8217;s current areas of focus.
In December 2024, Intra-Cellular Therapies submitted a marketing application to the FDA for Caplyta&nbsp;as an adjunctive treatment for adults with major depressive disorder (MDD).
In two global Phase 3 studies, Caplyta, as an adjunctive treatment to antidepressants, demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms, as measured by both clinician-rated and patient-reported outcomes.
If approved, Caplyta&nbsp;has the potential to be the first treatment approved for MDD and depressive symptoms associated with bipolar I and II in more than 15 years.
Additional Phase 3 trials are underway with Caplyta in bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania).
Johnson &amp; Johnson expects to fund the transaction through cash on hand and debt.
In 204, Bristol-Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) added an oral medication for&nbsp;schizophrenia via Karuna Therapeutics deal for $330 per share in cash for a total equity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">value of $14 billion</a>.
In November, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) released data from its two Phase 2 EMPOWER trials of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" rel="noreferrer noopener">emraclidine for schizophrenia</a>.
The patients experienced an acute exacerbation of psychotic symptoms and did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics.
Price Action: JNJ stock is up 0.86% at $143.28, and ITCI stock is up 34.5% at $127.62 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42945266/why-department-store-chain-macys-stocks-are-sliding-on-monday-premarket" target="_blank" rel="noreferrer noopener">Why Is Department Store Chain Macy&#8217;s Stock Sliding Today?</a></li>
</ul>
Photo by Tada Images via Shutterstock

Movers

Trading Ideas

ITCI

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal

ABCL

AbCellera Expands AbbVie Collaboration To Include Discovery Of T-Cell Engagers In Oncology

Simcere Zaiming And AbbVie Partner To Develop Novel Trispecific Antibody Candidate In Multiple Myeloma

Deep-pocketed investors have adopted a bullish approach towards AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 27% bearish. Among these notable options, 3 are puts, totaling $207,332, and 8 are calls, amounting to $422,158.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $210.0 for AbbVie over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $125.0 to $210.0 in the last 30 days. 
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736526625_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.05</td>
<td>$16.05</td>
<td>$16.05</td>
<td>$175.00</td>
<td>$134.3K</td>
<td>730</td>
<td align="right">118</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.6</td>
<td>$8.7</td>
<td>$9.6</td>
<td>$195.00</td>
<td>$96.8K</td>
<td>3.5K</td>
<td align="right">123</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$4.2</td>
<td>$3.95</td>
<td>$4.11</td>
<td>$190.00</td>
<td>$89.9K</td>
<td>1.4K</td>
<td align="right">219</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.6</td>
<td>$3.0</td>
<td>$3.6</td>
<td>$180.00</td>
<td>$72.0K</td>
<td>3.5K</td>
<td align="right">217</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$8.5</td>
<td>$8.25</td>
<td>$8.5</td>
<td>$170.00</td>
<td>$42.5K</td>
<td>932</td>
<td align="right">61</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
After a thorough review of the options trading surrounding AbbVie, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,402,809, the price of ABBV is down by -1.12%, reaching $176.5.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $215.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on AbbVie with a target price of $211. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on AbbVie, maintaining a target price of $220. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Markets

AbbVie Unusual Options Activity For January 10

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AbbVie, revealing an average target of $211.24, a high estimate of $231.00, and a low estimate of $191.00. This current average has increased by 0.55% from the previous average price target of $210.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1736362847_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of AbbVie among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$211.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$191.00</td>
<td>-</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$206.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$224.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$221.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Navin Jacob</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$231.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$203.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AbbVie's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AbbVie analyst ratings.</a>
<h2>Get to Know AbbVie Better</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining AbbVie's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.83% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AbbVie's net margin is impressive, surpassing industry averages. With a net margin of 10.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AbbVie's ROE excels beyond industry benchmarks, reaching 24.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: AbbVie's debt-to-equity ratio stands notably higher than the industry average, reaching 11.78. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing AbbVie: Insights From 17 Financial Analysts

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$142.00</td>
<td>$132.6K</td>
<td>236</td>
<td>1.1K</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$35.0K</td>
<td>3.7K</td>
<td>750</td>
</tr>
<tr>
<td>SOLV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$25.0K</td>
<td>711</td>
<td>608</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$92.50</td>
<td>$83.4K</td>
<td>14</td>
<td>340</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$210.00</td>
<td>$87.3K</td>
<td>2.5K</td>
<td>284</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$45.00</td>
<td>$28.6K</td>
<td>53.7K</td>
<td>193</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$110.00</td>
<td>$106.5K</td>
<td>210</td>
<td>101</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>184</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with neutral sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 829 contract(s) at a $142.00 strike. The total cost received by the writing party (or parties) was $132.6K, with a price of $160.0 per contract. There were 236 open contracts at this strike prior to today, and today 1103 contract(s) were bought and sold. 
• For CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $15.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3727 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding SOLV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $250.0 per contract. There were 711 open contracts at this strike prior to today, and today 608 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a call option sweep that happens to be bearish, expiring in 254 day(s) on September 19, 2025. This event was a transfer of 139 contract(s) at a $92.50 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $83.4K, with a price of $600.0 per contract. There were 14 open contracts at this strike prior to today, and today 340 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bullish sentiment. It expires in 373 day(s) on January 16, 2026. Parties traded 148 contract(s) at a $210.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $87.3K, with a price of $590.0 per contract. There were 2546 open contracts at this strike prior to today, and today 284 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option trade that happens to be bullish, expiring in 44 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $28.6K, with a price of $286.0 per contract. There were 53788 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 254 day(s) on September 19, 2025. Parties traded 101 contract(s) at a $110.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1055.0 per contract. There were 210 open contracts at this strike prior to today, and today 101 contract(s) were bought and sold. 
• For VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we notice a call option trade that happens to be neutral, expiring in 373 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $64.2K, with a price of $3210.0 per contract. There were 184 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

GEHC

SOLV

VEEV

8 Health Care Stocks Whale Activity In Today's Session

Truist Securities analyst Srikripa Devarakonda maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and lowers the price target from $215 to $211.

Price Target

Truist Securities Maintains Buy on AbbVie, Lowers Price Target to $211

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 3.09% on an annualized basis producing an average annual return of 15.5%. Currently, AbbVie has a market capitalization of $317.41 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,015.83 today based on a price of $179.75 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736291720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today

&nbsp;
Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&amp;D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
 &nbsp;
While acquired IPR&amp;D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&amp;D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on October&nbsp;30, 2024 excluded the impact of acquired IPR&amp;D and milestones expense that may be incurred beyond the third quarter of 2024. AbbVie's full-year 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR&amp;D and milestones expense, is $10.02 - $10.06. AbbVie's fourth quarter 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR&amp;D and milestones expense, is $2.06 - $2.10.

Guidance

AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</h3>
<ul>
<li>Dividend Yield: 3.67%</li>
<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and cut the price target from $344 to $310 on Jan. 2. This analyst has an accuracy rate of 66%.</li>
<li>B of A Securities analyst Tim Anderson reinstated an Underperform rating with a price target of $256 on Dec. 10. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Dec. 10, Amgen increased its first-quarter dividend by 6% from $2.25 to $2.38 per share.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">latest AMGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png" alt="" class="wp-image-716759" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-768x705.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.66%</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $191 on Dec. 10. This analyst has an accuracy rate of 63%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Dec. 13, AbbVie announced plans to acquire Nimble Therapeutics.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">latest ABBV news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png" alt="" class="wp-image-716760" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 6.02%</li>
<li>Deutsche Bank analyst George Hill upgraded the stock from Hold to Buy with a price target of $66 on Dec. 3. This analyst has an accuracy rate of 60%.</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and lowered the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: The DOJ recently alleged that CVS violated the Controlled Substances Act by filling unlawful prescriptions for opioid combinations and excessive quantities since 2013.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">CVS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png" alt="" class="wp-image-716761" style="width:584px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Acuity Brands Stock Ahead Of Q1 Earnings</a></li>
</ul>

Dividends

Pre-Market Outlook

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 3.51% since its last report. The company recently reported that it has 19.32 million shares sold short, which is 1.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735131612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into AbbVie's Recent Short Interest

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 1.88% on an annualized basis producing an average annual return of 15.25%. Currently, AbbVie has a market capitalization of $317.86 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $201.79 today based on a price of $180.00 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735073117_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today

The Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know">plaguing the fund. </a>
What To Know: The Schwab US Dividend Equity ETF is heavily weighted in the healthcare sector with four pharmaceutical stocks representing 15.83% of the fund's total holdings. The sector has underperformed recently as increased uncertainty emerged surrounding the potential appointments and <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">policy changes</a> that could come under President-elect Donald Trump.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/social-media/24/12/42598651/mystery-drone-sightings-all-over-the-country-trump-says-what-to-know-about-investigations-lawmakers-reactions">&#8216;Mystery Drone&#8217; Sightings Spark Investigations, Politicians Respond: &#8216;Shoot Them Down,&#8217; Trump Says</a>
<h2 class="wp-block-heading">Healthcare Holdings</h2>
Bristol-Meyers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is the fund's top pharmaceutical holding, representing 4.64% of its assets. The stock is down 2.6% over the past month. 
Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is also in the fund's top 10 holdings. It fell more than 5% following the presidential election as the vaccine-maker faces an uncertain political and regulatory environment ahead. 
AbbVie, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) round out the dividend-focused fund's healthcare holdings.  AbbVie shares are down slightly, though Amgen shares are down by more than 10% in December following disappointing <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair">clinical trial </a>results from its weight-loss drug candidate, MariTide. 
Interest Rates: Another factor that could be affecting the Schwab dividend-focused fund is the uncertain interest rate environment. Dividends tend to become more attractive to investors in a low-interest rate environment. Recent comments from the Federal Reserve suggest a more hawkish outlook with inflation remaining sticky and above the Fed's target rate of 2%.&nbsp;
Additionally, the incoming Trump administration could again play a factor as Trump has pledged to raise tariffs on foreign imports which could reignite inflation and lead to interest rates staying higher for longer.&nbsp;
When interest rates are high, the yields on bonds and other fixed-income securities become more competitive, making dividend yields less appealing by comparison.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

Politics

ETFs

SCHD

Schwab US Dividend Equity ETF Reverses In December: What's Going On?

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Analyst Color

ELAN

GILD

IDXX

PRGO

REGN

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) made an insider sell.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001551152/000141588924029754//Archives/edgar/data/1551152/000141588924029754/0001415889-24-029754-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Buckbee sold 1,800 shares of AbbVie. The total transaction amounted to $310,032. 
AbbVie's shares are actively trading at $172.41, experiencing a down of 0.35% during Thursday's morning session.
<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Understanding the Numbers: AbbVie's Finances</h3>
Revenue Growth: AbbVie displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 3.83%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 70.87%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): AbbVie's EPS reflects a decline, falling below the industry average with a current EPS of 0.88.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 11.78, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 60.29 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 5.52 is lower than the industry average, implying a discounted valuation for AbbVie's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): AbbVie's EV/EBITDA ratio, lower than industry averages at 20.27, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001551152">Check Out The Full List Of AbbVie's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock

MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from analysts. Read more… When markets get unpredictable, many investors turn to blue-chip stocks for stability. These companies are known for their solid financials, steady growth, and reliable dividends, making them a wise choice for anyone looking to weather economic ups and downs.
Below, I have highlighted three fundamentally strong blue-chip stocks from the healthcare and pharmaceutical sector: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), and Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>) that one could consider investing in the near term.
Healthcare stocks, in particular, have a reputation for being dependable. They often hold up well during tough economic times because the need for healthcare doesn't go away, no matter what the market is doing. In fact, healthcare is the third-largest industry in the S&amp;P 500, and it's poised for growth. PwC expects medical costs to <a href="https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.html">rise 8% in 2025</a> for group markets, driven by inflation, prescription drug spending, and higher demand for mental health services.
At the same time, inflation persists. In November, consumer prices <a href="https://www.cnbc.com/2024/12/11/cpi-inflation-november-2024-annual-inflation-rate-accelerates-to-2point7percent-in-november-as-expected.html">rose at a 2.7%</a> annual rate, slightly higher than in October. As a result, the Federal Open Market Committee adjusted its monetary policy, cutting the overnight borrowing rate to a target range of 4.25%-4.5%. With uncertainty looming over the stock market, investors can look to invest in blue-chip stocks that offer stability, value, and diversification, shielding investments from potential downturns.
With that in mind, let's evaluate the three <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> picks, beginning with the third choice.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in researching, developing, manufacturing, and selling healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine and MedTech segments.
On December 30, 2024, JNJ announced that the European Commission approved RYBREVANT&#xAE; (amivantamab) in combination with LAZCLUZE&#x2122; (lazertinib) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults with EGFR mutations. This chemotherapy-free combination has shown superior efficacy compared to Osimertinib monotherapy for treating EGFR-mutated NSCLC.
Last year, in August, JNJ acquired V-Wave Ltd., a privately held company specializing in innovative heart failure treatment. The deal included an upfront payment of $60 million, with the potential for additional payments of up to $1.1 billion. This acquisition is set to enhance JNJ MedTech's position in the cardiovascular space, broadening its portfolio of advanced heart failure treatment options.
For the third quarter of 2024, which ended on September 29, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its gross profit rose 5.2% from the year-ago value to $15.51 billion, while its adjusted net earnings from continuing operations amounted to $5.88 billion or $2.42 per share in the same period. Also, the company's <a href="https://www.investopedia.com/terms/f/freecashflow.asp">free cash flow</a> for the quarter increased 16.9% year-over-year to $14 billion.
As per the updated guidance for the fiscal year 2024, JNJ forecasts operational sales between $89.20 billion and $89.60 billion, a 6% increase from 2023, primarily driven by recent acquisitions. The company also expects adjusted EPS between $9.97 and $10.07.
The consensus revenue estimate of $88.79 billion for the fiscal year 2024, which ended on December 31, represents a 4.3% increase year-over-year. The consensus EPS estimate of $9.96 for the same period indicates a marginal improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
The stock has gained 1.1% year-to-date to close the last trading session at $146.23.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
JNJ has a B grade for Value, Stability, Sentiment, and Quality. It is ranked #14 out of 152 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth and Momentum).
Stock #2: Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global healthcare company offering health solutions through its prescription medicines, including biologic therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On January 8, 2025, MRK announced that China's National Medical Products Administration (NMPA) has approved GARDASIL&#xAE; (Human Papillomavirus Quadrivalent Vaccine, Types 6, 11, 16, and 18) for use in males aged 9 to 26. With this approval, GARDASIL became the first HPV vaccine authorized in China for preventing HPV-related cancers and diseases in males.
On November 19, the company's board of directors declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. This dividend was paid to its shareholders on January 8, 2025.
With 14 years of consecutive dividend growth, MRK's annual dividend of $3.24 translates to a yield of 3.21% on the current share price. Its four-year average yield is 2.87%. The company's dividend payout has grown at a CAGR of 6.1% over the past three years.
MRK's sales for the third quarter ended September 30, 2024, increased 4.4% year-over-year to $16.66 billion, while its KEYTRUDA product sales improved by 17.2% from the year-ago value to $ 7.43 billion. The company's non-GAAP net income and non-GAAP EPS for the quarter stood at $3.98 billion and $1.57, respectively.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.60 billion to $64.10 billion, an increase from the previous guidance of $63.40 billion to $64.40 billion. The company also expects non-GAAP EPS to be between $7.72 and $7.77.
Analysts expect MRK's revenue for the fourth quarter (ended December 2024) to increase 5.9% year-over-year to $15.49 billion, while its EPS for the same period is expected to grow significantly from the prior year to $1.80. Moreover, the company topped the consensus revenue estimates in each of the trailing four quarters.
The stock has gained marginally year-to-date to close the last trading session at $99.85.
It is no surprise that MRK has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It also has an A grade for Quality and a B for Value and Stability. Within the same industry, it is ranked #8 out of 152 stocks.
In addition to the POWR Rating grades I've just highlighted, you can see MRK's Growth, Momentum, and Sentiment ratings <a href="https://stocknews.com/stock/MRK/">here</a>.
Stock #1: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV is a global diversified research-based biopharmaceutical company engaged in manufacturing and selling medications and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties.
On December 13, 2024, ABBV announced the acquisition of Nimble Therapeutics to strengthen its immunology pipeline further. The deal includes Nimble's lead asset, an investigational oral peptide IL-23R inhibitor currently in preclinical development for psoriasis, as well as a pipeline of innovative oral peptide candidates targeting various autoimmune diseases with significant unmet needs.
Additionally, ABBV will gain access to Nimble's proprietary peptide synthesis, screening, and optimization platform, designed to enable the discovery and optimization of oral peptide therapeutics.
On October 30, the company's board of directors increased the quarterly dividend from $1.55 to $1.64 per share, payable on February 14, 2025 to the shareholders of record on January 15, 2025. This reflects an increase of approximately 5.8%, continuing ABBV's strong commitment to returning cash to shareholders through a growing dividend.
It pays an annual dividend of $6.56, which translates to a yield of 3.65% at the current share price. Its four-year average dividend yield is 3.89%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 7.7% over the past five years.
During the fiscal third quarter (ended September 30, 2024), ABBV's net revenue increased 3.8% year-over-year to $14.46 billion, while the company's Neuroscience segment reported net revenue of $2.36 billion, indicating a 15.6% growth from the prior-year quarter. ABBV's operating earnings came in at $3.83 billion, up 67.9% year-over-year, while its adjusted earnings per share grew 1.7% from the year-ago value to $3.
Looking ahead, ABBV forecasts full-year 2024 and raises its adjusted EPS to range between $10.90 and $10.94, from the prior forecast of $10.67 and $10.87.
Street expects ABBV's revenue and EPS for the fiscal fourth quarter (ended December 2024) to increase 3.5% and 3.4% year-over-year to $14.80 billion and $2.88, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Shares of ABBV have gained 6.7% over the past six months and 10.1% over the past year to close the last trading session at $178.50.
ABBV's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has a B grade for Growth, Value, Stability, Sentiment, and Quality. Out of 152 stocks in the Medical - Pharmaceuticals industry, ABBV is ranked #3. <a href="https://stocknews.com/stock/ABBV/">Click here</a> to see ABBV's rating for Momentum.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares fell $0.01 (-0.01%) in after-hours trading Wednesday. Year-to-date, JNJ has declined -1.62%, versus a 0.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/jnj-abbv-mrk-3-blue-chip-stocks-with-strong-buy-ratings-from-analysts/>3 Blue-Chip Stocks with Strong Buy Ratings from Analysts</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday. David Risinger has given ...

Optimistic Outlook on AbbVie's Emraclidine Strategy: A High-Reward Investment Opportunity

Income & Growth: 3 Of The Best Dividend Stocks For Any Market

Guggenheim analyst Vamil Divan lowered the firm's price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The firm is...

AbbVie price target lowered to $212 from $221 at Guggenheim

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs c...

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

The stock market has been volatile to kick off 2025, with many top tech stocks well off their highs as some investors question their lofty valuatio...

Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market

ALPMF

ALPMY

AZNCF

CGON

ILMN

IRWD

MLTX

RHHBY

RHHVF

RLAY

TBPH

TCHBF

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call

CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics

AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Contracts

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Comments

AbbVie

空売り

AbbVie (NYSE:ABBV) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル